On Nov. 6, 2020, Mesa Biotech announced it had been awarded a contract up to $13 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), for development of its rapid molecular diagnostic test for detection of SARS-CoV-2 & Flu A/Flu B in a single sample.

The Acculaﾙ SARS-CoV-2 & Flu A/Flu B Combination Test will provide Rapid PCR results in 30 minutes at the point of care (POC).